Protocol of a randomized controlled trial of the fear of recurrence therapy (FORT) intervention for women with breast or gynecological cancer

Christine Maheu, Sophie Lebel, Christine Courbasson, Monique Lefebvre, Mina Singh, Lori J Bernstein, Linda Muraca, Aronela Benea, Lynne Jolicoeur, Cheryl Harris, Agnihotram V Ramanakumar, Sarah Ferguson, Souraya Sidani, Christine Maheu, Sophie Lebel, Christine Courbasson, Monique Lefebvre, Mina Singh, Lori J Bernstein, Linda Muraca, Aronela Benea, Lynne Jolicoeur, Cheryl Harris, Agnihotram V Ramanakumar, Sarah Ferguson, Souraya Sidani

Abstract

Background: Clinically significant levels of fear of cancer recurrence (FCR) affect up to 49% of cancer survivors and are more prevalent among women. FCR is associated with psychological distress, lower quality of life, and increased use of medical resources. Despite its prevalence, FCR is poorly addressed in clinical care. To address this problem, we first developed, and pilot tested a 6-week, 2 h, Cognitive-existential group intervention therapy that targeted FCR in survivors of breast or gynecological cancer. Following the positive outcome of the pilot, we are now testing this approach in a randomized clinical trial (RCT). Goal and hypotheses: This multicenter, prospective RCT aims to test the efficacy of the intervention. The study hypotheses are that, compared to a control group, cancer survivors participating in the intervention (1) will have less FCR, (2) will show more favorable outcomes on the following measures: cancer-specific distress, quality of life, illness uncertainty, intolerance of uncertainty, perceived risk of cancer recurrence, and coping skills. We further postulate that the between-group differences will persist three and 6 months post-intervention.

Methods: Sixteen groups of seven to nine women are being allocated to the intervention or the control group. The control group receives a 6-week, 2 h, structurally equivalent support group. We are recruiting 144 cancer survivors from four hospital sites in three Canadian cities. The sample size was based on the moderate pre/post-test changes found in our pilot study and adjusted to the drop-out rates.

Measurements: The primary outcome, FCR, is measured by the Fear of Cancer Recurrence Inventory. Secondary outcomes measured include cancer-specific distress, perceived risk of cancer recurrence, illness uncertainty, intolerance of uncertainty, coping, and quality of life. We use reliable and recognized valid scales. Participants are to complete the questionnaire package at four times: before the first group session (baseline), immediately after the sixth session, and 3 and 6 months post-intervention.

Analysis: In the descriptive analysis, comparison of group equivalent baseline variables, identification of confounding/intermediate variables and univariate analysis are planned. Each participant's trajectory is calculated using Generalized Estimating Equation models to determine the time and group effects, after considering the correlation structures of the groups. An intent-to-treat analysis approach may be adopted.

Discussion: Our Fear of Recurrence Therapy (FORT) intervention has direct implications for clinical service development to improve the quality of life for patients with breast (BC) and gynecological cancer (GC). Based on our pilot data, we are confident that the FORT intervention can guide the development of effective psychosocial cancer survivorship interventions to reduce FCR and improve psychological functioning among women with BC or GC.

Trial registration: Dr. Christine Maheu registered the trial with ISRCTN registry (Registration number: ISRCTN83539618, date assigned 03/09/2014).

Keywords: BREAST cancer; Cancer distress; Cognitive-existential group therapy; Coping; Fear of cancer recurrence; Gynecological cancer; Quality of life; Randomized clinical trial.

References

    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics: Canadian Cancer Statistics. 2015. []. Accessed 1 Oct 2015.
    1. Vickberg SM. The concerns about recurrence scale (CARS): a systematic measure of women’s fears about the possibility of breast cancer recurrence. Ann Behav Med. 2003;25(1):16–24. doi: 10.1207/S15324796ABM2501_03.
    1. Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7(3):300–322. doi: 10.1007/s11764-013-0272-z.
    1. Baker F, Denniston M, Smith T, West MM. Adult cancer survivors: how are they faring? Cancer. 2005;104(11 Suppl):2565–2576. doi: 10.1002/cncr.21488.
    1. Herschbach P, Keller M, Knight L, Brandl T, Huber B, Henrich G, et al. Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire. Br J Cancer. 2004;91(3):504–11.
    1. Koch L, Bertram H, Eberle A, Holleczek B, Schmid-Hopfner S, Waldmann A, Zeissig SR, Brenner H, Arndt V. Fear of recurrence in long-term breast cancer survivors-still an issue. Results on prevalence, determinants, and the association with quality of life and depression from the cancer survivorship--a multi-regional population-based study. Psycho-Oncology. 2014;23(5):547–554. doi: 10.1002/pon.3452.
    1. Park CL, Cho D, Blank TO, Wortmann JH. Cognitive and emotional aspects of fear of recurrence: predictors and relations with adjustment in young to middle-aged cancer survivors. PON Psycho-Oncology. 2013;22(7):1630–1638. doi: 10.1002/pon.3195.
    1. Mehnert A, Koch U, Sundermann C, Dinkel A. Predictors of fear of recurrence in patients one year after cancer rehabilitation: a prospective study. Acta Oncologica (Stockholm, Sweden) 2013;52(6):1102–1109. doi: 10.3109/0284186X.2013.765063.
    1. Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241–251. doi: 10.1007/s00520-008-0444-y.
    1. Crist JV, Grunfeld EA. Factors reported to influence fear of recurrence in cancer patients: a systematic review. Psycho-Oncology. 2012;22(5):978–986. doi: 10.1002/pon.3114.
    1. Thewes B, Butow P, Zachariae R, Christensen S, Simard S, Gotay C. Fear of cancer recurrence: a systematic literature review of self-report measures. Psycho-Oncology. 2012;21(6):571–587. doi: 10.1002/pon.2070.
    1. Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer-related intrusive cognitions in breast cancer survivors. Psycho-Oncology. 2009;18(12):1273–1280. doi: 10.1002/pon.1481.
    1. Kim Y, Carver CS, Spillers RL, Love-Ghaffari M, Kaw CK. Dyadic effects of fear of recurrence on the quality of life of cancer survivors and their caregivers. Qual Life Res. 2012;21(3):517–525. doi: 10.1007/s11136-011-9953-0.
    1. Montel S. Fear of recurrence: a case report of a woman breast cancer survivor with GAD treated successfully by CBT. Clin Psychol Psychother. 2010;17(4):346–353.
    1. Simard S, Savard J, Ivers H. Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv. 2010;4(4):361–371. doi: 10.1007/s11764-010-0136-8.
    1. Taha SA, Matheson K, Anisman H. Everyday experiences of women posttreatment after breast cancer: the role of uncertainty, hassles, uplifts, and coping on depressive symptoms. J Psychosoc Oncol. 2012;30(3):359–379. doi: 10.1080/07347332.2012.664259.
    1. Glynne-Jones R, Chait I, Thomas SF. When and how to discharge cancer survivors in long term remission from follow-up: the effectiveness of a contract. Clin Oncol (R Coll Radiol) 1997;9(1):25–29. doi: 10.1016/S0936-6555(97)80055-6.
    1. Hart SL, Latini DM, Cowan JE, Carroll PR. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer. 2008;16(2):161–169. doi: 10.1007/s00520-007-0296-x.
    1. Llewellyn CD, Weinman J, McGurk M, Humphris G. Can we predict which head and neck cancer survivors develop fears of recurrence. J Psychosom Res. 2008;65(6):525–532. doi: 10.1016/j.jpsychores.2008.03.014.
    1. Lebel S, Rosberger Z, Edgar L, Devins GM. Comparison of four common stressors across the breast cancer trajectory. J Psychosom Res. 2007;63(3):225–232. doi: 10.1016/j.jpsychores.2007.02.002.
    1. Armes J, Crowe M, Colbourne L, Morgan H, Murrells T, Oakley C, Palmer N, Ream E, Young A, Richardson A. Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol. 2009;27(36):6172–6179. doi: 10.1200/JCO.2009.22.5151.
    1. Hodgkinson K, Butow P, Hunt GE, Pendlebury S, Hobbs KM, Wain G. Breast cancer survivors’ supportive care needs 2–10 years after diagnosis. Support Care Cancer. 2007;15(5):515–523. doi: 10.1007/s00520-006-0170-2.
    1. Lebel S, Tomei C, Feldstain A, Beattie S, McCallum M. Does fear of cancer recurrence predict cancer survivors’ health care use? Support Care Cancer. 2013;21(3):901–906. doi: 10.1007/s00520-012-1685-3.
    1. Sarkar S, Sautier L, Schilling G, Bokemeyer C, Koch U, Mehnert A. Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. J Cancer Surviv. 2015;9(4):567–575. doi: 10.1007/s11764-015-0434-2.
    1. Koch L, Jansen L, Brenner H, Arndt V. Fear of recurrence and disease progression in long-term (5 years) cancer survivors--a systematic review of quantitative studies. Psycho-oncology. 2013;22(1):1–11. doi: 10.1002/pon.3022.
    1. Maheu C, Lebel S, Tomei C, Singh M, Esplen MJ. Breast and ovarian cancer survivors’ experience of participating in a cognitive-existential group intervention addressing fear of cancer recurrence. YEJON Eur. J. Oncol. Nurs. 2015;19(4):433–440. doi: 10.1016/j.ejon.2014.12.003.
    1. Lebel S, Maheu C, Lefebvre M, Secord S, Courbasson C, Singh M, Jolicoeur L, Benea A, Harris C, Fung MF, et al. Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study. J Cancer Surviv. 2014;8(3):485–496. doi: 10.1007/s11764-014-0357-3.
    1. Smith A, Thewes B, Turner J, Gilchrist J, Fardell J, Sharpe L, Bell ML, Girgis A, Grier M, Byrne D, et al. Pilot of a theoretically grounded psychologist-delivered intervention for fear of cancer recurrence (Conquer Fear) Psycho-Oncology. 2015;24(8):967–70. doi: 10.1002/pon.3775.
    1. van de Wal MA, Gielissen MF, Servaes P, Knoop H, Speckens AE, Prins JB. Study protocol of the SWORD-study: a randomised controlled trial comparing combined online and face-to-face cognitive behaviour therapy versus treatment as usual in managing fear of cancer recurrence. BMC Psychology. 2015;3(1):12. doi: 10.1186/s40359-015-0068-1.
    1. Butow PN, Bell ML, Smith AB, Fardell JE, Thewes B, Turner J, Gilchrist J, Beith J, Girgis A, Sharpe L, et al. Conquer fear: protocol of a randomised controlled trial of a psychological intervention to reduce fear of cancer recurrence. BMC Cancer. 2013;13(1):201. doi: 10.1186/1471-2407-13-201.
    1. Herschbach P, Berg P, Waadt S, Duran G, Engst-Hastreiter U, Henrich G, Book K, Dinkel A. Group psychotherapy of dysfunctional fear of progression in patients with chronic arthritis or cancer. Psychother Psychosom. 2010;79(1):31–38. doi: 10.1159/000254903.
    1. Humphris G, Ozakinci G. The AFTER intervention: a structured psychological approach to reduce fears of recurrence in patients with head and neck cancer. Br J Health Psychol. 2008;13(Pt 2):223–230. doi: 10.1348/135910708X283751.
    1. Lengacher CA, Johnson-Mallard V, Post-White J, Moscoso MS, Jacobsen PB, Klein TW, Klein TW, Widen RH, Fitzgerald SG, Shelton MM, Barta M et al. Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psycho-Oncology. 2009;18(12):1261–72.
    1. Lengacher CA, Johnson-Mallard V, Barta M, Fitzgerald S, Moscoso MS, Post-White J, Jacobsen PB, Molinari Shelton M, Le N, Budhrani P, et al. Feasibility of a mindfulness-based stress reduction program for early-stage breast cancer survivors. J Holist Nurs. 2011;29(2):107–117. doi: 10.1177/0898010110385938.
    1. Cameron LD, Booth RJ, Schlatter M, Ziginskas D, Harman JE. Changes in emotion regulation and psychological adjustment following use of a group psychosocial support program for women recently diagnosed with breast cancer. Psycho-Oncology. 2007;16(3):171–180. doi: 10.1002/pon.1050.
    1. Shields CG, Ziner KW, Bourff SA, Schilling K, Zhao Q, Monahan P, Sledge G, Champion V. An intervention to improve communication between breast cancer survivors and their physicians. J Psychosoc Oncol. 2010;28(6):610–629. doi: 10.1080/07347332.2010.516811.
    1. Kissane DW, Bloch S, Miach P, Smith GC, Seddon A, Keks N. Cognitive-existential group therapy for patients with primary breast cancer--techniques and themes. Psycho-Oncology. 1997;6(1):25–33. doi: 10.1002/(SICI)1099-1611(199703)6:1<25::AID-PON240>;2-N.
    1. Kissane DW, Bloch S, Smith GC, Miach P, Clarke DM, Ikin J, Love A, Ranieri N, McKenzie D. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial. Psycho-Oncology. 2003;12(6):532–546. doi: 10.1002/pon.683.
    1. Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, Hunter MS. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–318. doi: 10.1016/S1470-2045(11)70364-3.
    1. Kissane DW. Reducing fear in cancer survivors. Aust Fam Physician. 1994;23(5):888–892.
    1. Kissane DW, Love A, Hatton A, Bloch S, Smith G, Clarke DM, Miach P, Ikin J, Ranieri N, Snyder RD. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol. 2004;22(21):4255–4260. doi: 10.1200/JCO.2004.12.129.
    1. Lee-Jones C, Humphris G, Dixon R, Hatcher MB. Fear of cancer recurrence--a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psycho-Oncology. 1997;6(2):95–105. doi: 10.1002/(SICI)1099-1611(199706)6:2<95::AID-PON250>;2-B.
    1. Edelman S, Kidman AD. Description of a group cognitive behaviour therapy programme with cancer patients. Psycho-Oncology. 1999;8(4):306–314. doi: 10.1002/(SICI)1099-1611(199907/08)8:4<306::AID-PON387>;2-Y.
    1. Spiegel D, Morrow GR, Classen C, Raubertas R, Stott PB, Mudaliar N, Pierce HI, Flynn PJ, Heard L, Riggs G. Group psychotherapy for recently diagnosed breast cancer patients: a multicenter feasibility study. Psycho-Oncology. 1999;8(6):482–493. doi: 10.1002/(SICI)1099-1611(199911/12)8:6<482::AID-PON402>;2-W.
    1. van den Beuken-van Everdingen MHJ, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patijn J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. Psycho-Oncology. 2008;17(11):1137–1145. doi: 10.1002/pon.1340.
    1. Wenzel LB, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz N, Cella D. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psycho-Oncology. 2002;11(2):142–153. doi: 10.1002/pon.567.
    1. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. Psychosom Med. 1979;41(3):209–218. doi: 10.1097/00006842-197905000-00004.
    1. Sundin EC, Horowitz MJ. Impact of event scale: psychometric properties. Br J Psychiatry. 2002;180:205–209. doi: 10.1192/bjp.180.3.205.
    1. Cameron LD, Leventhal H. The self-regulation of health and illness behaviour. New York: Routledge; 2003.
    1. Mishel M. Uncertainty in illness. Image J Nurs Sch. 1988;20(4):225–232. doi: 10.1111/j.1547-5069.1988.tb00082.x.
    1. Ladouceur R, Dugas MJ, Freeston MH, Leger E, Gagnon F, Thibodeau N. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Consult Clin Psychol. 2000;68(6):957–964. doi: 10.1037/0022-006X.68.6.957.
    1. Easterling DV, Leventhal H. Contribution of concrete cognition to emotion: neutral symptoms as elicitors of worry about cancer. J Appl Psychol. 1989;74(5):787–796. doi: 10.1037/0021-9010.74.5.787.
    1. Lasry JC, Margolese RG. Fear of recurrence, breast-conserving surgery, and the trade-off hypothesis. Cancer. 1992;69(8):2111–2115. doi: 10.1002/1097-0142(19920415)69:8<2111::AID-CNCR2820690817>;2-T.
    1. Skaali T, Fossa SD, Bremnes R, Dahl O, Haaland CF, Hauge ER, Klepp O, Oldenburg J, Wist E, Dahl AA. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology. 2009;18(6):580–588. doi: 10.1002/pon.1437.
    1. Stanton AL, Danoff-Burg S, Huggins ME. The first year after breast cancer diagnosis: hope and coping strategies as predictors of adjustment. Psycho-Oncology. 2002;11(2):93–102. doi: 10.1002/pon.574.
    1. Mishel MH. The measurement of uncertainty in illness. Nurs Res. 1981;30(5):258–263. doi: 10.1097/00006199-198109000-00002.
    1. Yalom I, Leszcz M, editors. The Theory and Practice of Group Psychotherapy. 5. New York: Basic Books; 2005.
    1. Safer DL, Hugo EM. Designing a control for a behavioral group therapy. Behav Ther. 2006;37(2):120–130. doi: 10.1016/j.beth.2005.06.001.
    1. Horner S, Rew L, Torres R. Enhancing intervention fidelity: a means of strengthening study impact. J Spec Pediatr Nurs. 2006;11(2):80–89. doi: 10.1111/j.1744-6155.2006.00050.x.
    1. Santacroce SJ, Maccarelli LM, Grey M. Intervention fidelity. Nurs Res. 2004;53(1):63–66. doi: 10.1097/00006199-200401000-00010.
    1. Zauszniewski JA. Intervention development: assessing critical parameters from the intervention recipient’s perspective. Appl Nurs Res. 2012;25(1):31–39. doi: 10.1016/j.apnr.2010.06.002.
    1. Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481–491. doi: 10.1007/s11764-015-0424-4.
    1. Thewes B, Meiser B, Hickie IB. Psychometric properties of the impact of event scale amongst women at increased risk for hereditary breast cancer. Psycho-Oncology. 2001;10(6):459–468. doi: 10.1002/pon.533.
    1. Bish A, Sutton S, Jacobs C, Levene S, Ramirez A, Hodgson S. Changes in psychological distress after cancer genetic counselling: a comparison of affected and unaffected women. Br J Cancer. 2002;86(1):43–50. doi: 10.1038/sj.bjc.6600030.
    1. Buhr K, Dugas MJ. The intolerance of uncertainty scale: psychometric properties of the english version. Behav Res Ther. 2002;40(8):931–945. doi: 10.1016/S0005-7967(01)00092-4.
    1. Mishel MH. Reconceptualization of the uncertainty in illness theory. Image J Nurs Sch. 1990;22(4):256–262. doi: 10.1111/j.1547-5069.1990.tb00225.x.
    1. Sexton KA, Dugas MJ. The cognitive avoidance questionnaire: validation of the English translation. J Anxiety Disord. 2008;22(3):355–370. doi: 10.1016/j.janxdis.2007.04.005.
    1. Lucock MP, Morley S. The health anxiety questionnaire. Br J Health Psychol. 1996;1:137–150. doi: 10.1111/j.2044-8287.1996.tb00498.x.
    1. Speckens AEM, Spinhoven P, Van Hemert AM, Bolk JH. The Reassurance Questionnaire (RQ): psychometric properties of a self-report questionnaire to assess reassurability. Psychol Med. 2000;30:841–847. doi: 10.1017/S0033291799002378.
    1. Zebrack BJ, Ganz PA, Bernaards CA, Petersen L, Abraham L. Assessing the impact of cancer: development of a new instrument for long-term survivors. Psycho-Oncology. 2006;15(5):407–421. doi: 10.1002/pon.963.
    1. Joseph S. Psychometric evaluation of Horowitz’s impact of event scale: a review. J Trauma Stress. 2000;13(1):101–113. doi: 10.1023/A:1007777032063.
    1. Ware J, Kosinski M, Dewey J, Gandek B. How to score and interpret single-item health status measures: a manual for users of the SF-8 health survey. Boston: QualyMetric; 2001.
    1. Roberts B, Browne J, Ocaka KF, Oyok T, Sondorp E. The reliability and validity of the SF-8 with a conflict-affected population in northern Uganda. Health Qual Life Outcomes. 2008;6:108. doi: 10.1186/1477-7525-6-108.
    1. Treadwell T, Laverture N, Kumar VK, Veeraraghavan V. The group cohesion scale-revised: reliability and validity. Int J Action Methods. 2001;54:3–12.
    1. Robak RW, Kangos KA, Chiffriller SH, Griffin PW. The working alliance in group counseling: an exploratory study. Psychol Rep. 2013;113(2):591–604. doi: 10.2466/21.02.PR0.113x19z7.
    1. Gaston L. Reliability and criterion-related validity of the California Psychotherapy Alliance scales-patient version. J Consult Clin Psychol. 1991;3(1):68–74.
    1. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73–86. doi: 10.1016/S0005-7916(00)00012-4.
    1. Herschbach P, Book K, Dinkel A, Berg P, Waadt S, Duran G, Engst-Hastreiter U, Henrich G. Evaluation of two group therapies to reduce fear of progression in cancer patients. Support Care Cancer. 2010;18(4):471–479. doi: 10.1007/s00520-009-0696-1.
    1. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2(3):109–112. doi: 10.4103/2229-3485.83221.
    1. Sauer BC, Brookhart MA, Roy J, VanderWeele T. A review of covariate selection for non-experimental comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(11):1139–1145. doi: 10.1002/pds.3506.
    1. Tomei C, Lebel S, Maheu C, Mutsaers B. Addressing fear of recurrence: improving psychological care in cancer survivors. Support Care Cancer. 2016.[Epub ahead of print].

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться